Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome by Mishina, T et al.
Cyclin D1 is a member of the G1 cyclin family involved in the
regulation of the G1–S transition of the cell cycle (Matsushime et
al, 1991; Motokura et al, 1991), perhaps the most important check-
point in the mammalian cell cycle (Weinberg, 1995; Sherr, 1996).
It mediates the phosphorylation and functional inactivation of
retinoblastoma (RB) protein in association with the cyclin-depen-
dent kinases CDK4 and CDK6. Hyperphosphorylation of RB
protein leads to its dissociation from transcription factors such as
E2F-1 that transcriptionally regulate growth-promoting genes.
p16INK4 (p16) protein inhibits CDK4- and CDK6-mediated phos-
phorylation of RB protein (Serrano et al, 1993; Hannon et al, 1994).
We have previously demonstrated altered p16 and RB protein
status in non-small-cell lung cancers (NSCLCs) and their potential
synergistic effect with altered p53 protein on proliferative activity
(Kinoshita et al, 1996). On the other hand, amplification and/or
increased expression of the cyclin D1 gene have been reported in
several kinds of human cancer, including those derived from the
oesophagus, head and neck, liver, and breast, with prognostic
importance in most of these cancers (Nishida et al, 1994; McIntosh
et al, 1995; Naitoh et al, 1995; Åkervall et al, 1997). The associa-
tion of cyclin D1 with cancer has led to the investigation of its
oncogenic properties in vitro and in vivo. Cyclin D1 can either
cooperate with the ras oncogene (Lovec et al, 1994) or complement
a defective adenovirus E1a oncogene (Hinds et al, 1994) to trans-
form cultured cells. In addition, targeting of the cyclin D1 gene by
the MMTV promoter and by an Epstein–Barr virus promoter has
been shown to result in mammary hyperplasia and carcinomas
(Wang et al, 1994) and in premalignant dysplasia of the tongue,
oesophagus and forestomach (Nakagawa et al, 1997) respectively,
in transgenic mice. However, little is known about the cell–biolog-
ical and clinical implications of cyclin D1 in NSCLCs, although its
expression has been reported in resected NSCLCs (Shapiro et al,
1995; Betticher et al, 1996, 1997; Mate et al, 1996; Nishio et al,
1997; Marchetti et al, 1998; Tanaka et al, 1998).
In the present study, we examined cyclin D1 expression by
immunohistochemistry in the same cohort of resected NSCLCs as
in our previous study (Kinoshita et al, 1996), and the amount of the
cyclin D1 gene by Southern blot analysis in a subset of tumours.
Cyclin D1 expression was analysed in relation to the status of p53,
p16 and RB proteins, to the proliferative activity determined by
the Ki-67 index, and to clinical outcome.
MATERIALS AND METHODS
Tumour specimens and survival data
Primary tumour specimens from 111 NSCLCs were obtained by
surgery from the Hokkaido University Medical Hospital, Sapporo
Minami-Ichijo Hospital and National Sapporo Minami Hospital
during 1990 and 1995. Tumours were snap-frozen in liquid
nitrogen and stored at –80°C in OCT compound (Miles, Elkhart,
IN, USA) for immunohistochemistry. For 29 specimens, portions
of the tumour were also snap-frozen and stored at –80°C for
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Correspondence to: H Dosaka-Akitagenomic DNA preparation. Adjacent non-frozen blocks were
fixed in 10% neutral buffered formalin and embedded in paraffin,
and then several sections from each specimen were stained with
haematoxylin and eosin to observe histopathology. According to
the 1981 WHO classification (WHO, 1982), they were histopatho-
logically diagnosed as adenocarcinoma (n = 71), squamous cell
carcinoma (n = 34) and large cell carcinoma (n = 6). The post-
surgical pathologic tumour, node, metastasis stage (pTNM) was
determined according to the guidelines of the American Joint
Committee on Cancer (Beahrs et al, 1992).
Of 111 NSCLCs, 92 tumours were potentially curatively
resected. Of the 92 patients, survival was analysed for the 77
patients who met the following criteria: (1) they survived for more
than 3 months after surgery; (2) did not die of causes other than
lung cancer within 5 years after surgery; and (3) were followed up
for more than 2 years after surgery (for patients who remained
alive). Eleven patients who did not meet the above criteria (two
died within 3 months after surgery, five died of causes other than
lung cancer within 5 years after surgery, four were followed up for
no more than 2 years after surgery), and four patients for whom no
survival records after surgery were obtained were excluded from
the present study. Tumour specimens were histopathologically
diagnosed as adenocarcinoma (n = 50), squamous cell carcinoma
(n = 22) and large cell carcinoma (n = 5). They represented 52 stage
I, nine stage II and 16 Stage IIIA tumours. Twenty-four patients
received combination chemotherapy as post-surgical treatment.
Radiation therapy was not performed before or after surgery for any
patients. Because all the patients enrolled in the current study were
coded, they could not be individually identified.
Immunohistochemistry for cyclin D1
Five-micrometer frozen sections of NSCLC specimens were fixed
in 3.7% formaldehyde in phosphate-buffered saline (PBS) (pH 7.2)
at room temperature for 10 min, and microwave pretreatment in
10 mM citrate buffer (pH 6.0) was performed for 10 min to retrieve
the antigenicity. The sections were then immersed in methanol
containing 0.6% hydrogen peroxide for 20 min to block the endoge-
nous peroxide activity, and were incubated with normal rabbit serum
to block the non-specific antibody binding sites. The sections were
consecutively reacted with mouse monoclonal anti-human cyclin
D1 antibody DCS-6 (Bartkova et al, 1994; Lukas et al, 1994a)
(Oncogene Science, Inc., Manhasset, NY, USA) or with control
mouse isotype-specific immunoglobulin at 4°C overnight.
Immunostaining was performed by the biotin–streptavidin immuno-
peroxidase method with 3,3¢-diaminobenzidine as a chromogen
(SAB-PO kit; Nichirei, Tokyo, Japan). Methyl green was used for
counterstain. An oesophageal cancer specimen with cyclin D1
expression (courteously provided by Dr M Fujita of the Department
of Pathology, National Sapporo Hospital, Sapporo, Japan), was used
as a positive control each time. Tumours were regarded as cyclin
D1-positive (+) if at least more than several malignant cells had
nuclear staining by observing one whole specimen from each
tumour. Tumours were scored as cyclin D1-negative (–) if all malig-
nant cells had no nuclear staining. All immunohistochemical studies
were done without knowledge of the clinical data.
Southern blot analysis
Genomic DNA was extracted from 29 NSCLC tumour specimens,
25 of which were studied for cyclin D1 expression by immunohisto-
chemistry. Southern blotting was carried out after digestion with
EcoRI, and hybridized to [a-32P]dCTP-labelled human cyclin D1
cDNA (kindly provided by Dr A Arnold, Massachusetts General
Hospital, Boston, MA, USA) and cardiac actin cDNA (kindly
provided by Dr F Gunning, Stanford University and Veterans
Affairs Medical Center, Palo Alto, CA, USA). The final wash
was performed twice in 0.2 ´ saline–sodium citrate (SSC), 0.1%
sodium dodecyl sulphate (SDS) at 50°C for 20 min. The blots were
then exposed to Kodak XAR-5 film (Kodak, Rochester, NY, USA)
and quantitatively analysed using a densitometer. The autoradio-
graphs were developed at various times to ensure that this analysis
was performed in the linear range of the film. The cyclin D1 signal
intensity was normalized against the cardiac actin signal intensity.
The relative cyclin D1 gene amount was defined as the normalized
cyclin D1 signal intensity in the tumour samples relative to that in
the normal lung control (= 1.0). The cyclin D1 gene was considered
to be amplified when the relative cyclin D1 gene amount was more
than 3.0, excluding the possibility of chromosomal aneuploidy.
Ki-67 staining and immunohistochemistry for p53, p16
and RB proteins
For Ki-67 staining, and immunohistochemistry for p53, p16 and
RB proteins, the slides and results that had been previously
reported (Kinoshita et al, 1996) were used for the current study.
All immunohistochemical studies were done without knowledge
of the clinical data.
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Table 1 Relationship between cyclin D1 expression and various
characteristics in 111 resected NSCLCs
Cyclin D1 expression
Characteristic (–) (+) P
Age (years, mean ± s.d.) 63.3 ± 9.0 64.1 ± 12.1 0.8
Gender
Male 72 9 0.7
Female 26 4
Smoking (pack years)
0–19 27 6 0.2
³ 20 71 7
Histological typea
Adeno 62 9 0.7
Squamous 30 4
Large 6 0
pT classification
T1 30 1 0.1
T2–4 68 12
pN classification
N0 61 9 0.5
N1–3 36 3
pM classification
M0 91 12 1.0
M1 7 1
pStage
I 52 8 0.8
II 11 0
IIIa 23 3
IIIb 6 1
IV 6 1
aAdeno, adenocarcinoma; Squamous, squamous cell carcinoma; Large, large
cell carcinoma.Statistical analysis
The associations between cyclin D1 expression and categorical vari-
ables were analysed by the c2 test or Fisher’s exact test as appro-
priate. The associations between cyclin D1 expression and age were
analysed by Student’s t-test. The differences of Ki-67 indices
between two groups were determined by the Mann–Whitney U-test.
The survival curves were estimated using the Kaplan–Meier
method, and differences in survival distributions were evaluated by
the log-rank test. Cox’s proportional hazards modelling of factors
potentially related to survival was performed to identify which
factors might have a significant influence on survival. The signifi-
cance level chosen was P < 0.05, and all tests were two-sided.
RESULTS
To determine cyclin D1 expression in tumour cells of NSCLCs, we
subjected fresh-frozen tissues from 111 resected NSCLCs to
immunohistochemistry for the protein. Cyclin D1 was expressed
in 13 (11.7%) of 111 NSCLCs. Typical cyclin D1+ and cyclin D1–
tumours are shown in Figure 1. All cyclin D1+ tumours had clear
but weak to moderate nuclear staining, which was confined to a
part of the tumour. Cytoplasmic staining was not observed in any
tumour cells. On the other hand, normal epithelial cells, tumour
stroma cells, and accompanying inflammatory cells were negative
for cyclin D1 expression.
To explore the mechanisms of cyclin D1 expression, Southern
blot analysis of the cyclin D1 gene was performed in 29 resected
NSCLCs, since amplification of this gene is implicated in its
expression in various types of tumours (Jiang et al, 1992; Buckley
et al, 1993). However, the cyclin D1 gene was not significantly
amplified and no rearranged bands were found in the 29 NSCLCs
examined (Figure 2).
After completion of immunohistochemical analysis of cyclin
D1, the status of this protein was statistically analysed to correlate
it with clinical, clinicopathological and molecular biological char-
acteristics. Cyclin D1 expression was found more frequently in
tumours with advanced pT status than in pT1 tumours (12 of 80
pT2–4 tumours vs only one of 30 pT1 tumours), but this associa-
tion was not statistically significant (P = 0.1) (Table 1). No other
significant association between cyclin D1 expression and other
clinical or clinicopathological parameters was observed.
Since cyclin D1 has been shown to be involved in the regulation
of the G1–S transition of the cell cycle (Weinberg, 1995; Sherr,
1996), cyclin D1 expression was analysed in relation to the prolif-
erative activity of tumours determined by the Ki-67 index, and to
the status of p53, p16 and RB proteins involved in the G1–S tran-
sition control. The Ki-67 index tended to be higher in cyclin D1+
tumours than in cyclin D1– tumours, although this difference was
not statistically significant (P = 0.08) (Table 2). Cyclin D1 expres-
sion was found significantly more frequently in tumours with
altered p53 protein expression compared to tumours without it
(P = 0.04), whereas it did not correlate with p16 or RB protein
status (Table 2). Because p16 and RB proteins are indicated to
function in a single regulatory pathway of the cell cycle (Serrano
et al, 1993; Lukas et al, 1995) and are reciprocally lost in NSCLCs
(Shapiro et al, 1995; Kinoshita et al, 1996), we divided the
tumours into two groups, the tumours retaining both p16 and RB
protein expression (p16+ and RB+; p16/RB+) and the tumours
lacking either p16 or RB protein expression (p16– or RB–;
p16/RB–). The difference in cyclin D1 expression between the two
groups of tumours was not statistically significant (Table 2).
Finally, we analysed the relationship between cyclin D1 expres-
sion and post-surgical survival for 77 patients whose tumours were
potentially curatively resected. Patients with cyclin D1+ tumours
survived longer than patients with cyclin D1– tumours (5-year
survival rates, 89% and 64% respectively; P = 0.045) (Figure 3),
and cyclin D1 expression tended to be a favourable prognostic
factor in univariate analysis (P = 0.08) (Table 3).
Cyclin D1 expression in NSCLCs 1291
British Journal of Cancer (1999) 80(8), 1289–1295 © 1999 Cancer Research Campaign 
AB
Figure 1 Immunohistochemical staining patterns for cyclin D1 in primary NSCLCs. Representative cyclin D1-negative large-cell carcinoma displays no nuclear
staining of cyclin D1 (A). Representative cyclin D1-positive adenocarcinoma shows moderate nuclear staining of cyclin D1 (B)DISCUSSION
The present study demonstrated expression of cyclin D1 without
amplification of its gene in primary NSCLCs. Cyclin D1 expres-
sion was frequently found in tumours with altered p53 protein
expression, and cyclin D1+ tumours showed higher proliferative
activity determined by the Ki-67 index than cyclin D1– tumours.
Furthermore, cyclin D1 expression was associated with a
favourable clinical outcome. In addition, cyclin D1 expression was
found in both p16/RB+ and p16/RB– NSCLCs in this study,
results consistent with previous studies (Shapiro et al, 1995;
Tanaka et al, 1998).
The frequency and subcellular localization of cyclin D1 expres-
sion determined by immunohistochemistry varied among studies
including the present study (Betticher et al, 1996; Nishio et al,
1997). We found cyclin D1 expression in 13 (11.7%) of 111
NSCLCs invariably in nucleus of tumour cells. Betticher et al
(1996) reported nuclear staining of cyclin D1 in ten (18.9%) of 53
NSCLCs and its cytoplasmic staining in 22 (41.5%) of 53
NSCLCs. On the other hand, nuclear staining of cyclin D1 was
detected in 81 (38.9%) of 208 NSCLCs by Nishio et al (1997).
Positive cytoplasmic staining in a few squamous cell carcinomas
was not scored as positive staining in the study. These discrepan-
cies of frequency and subcellular localization of cyclin D1 expres-
sion may be attributed not only to the difference of antibodies and
antigen retrieval methods used, but also to the difference of fixa-
tion and preservation of materials: we used fresh, rapidly frozen
tissues and fixed them in formaldehyde, although the two previous
studies used archival formalin-fixed paraffin-embedded tissues.
In the absence of amplification and rearrangement of the cyclin
D1 gene, mechanisms other than these may be responsible for
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Figure 2 Southern blot analysis of the cyclin D1 gene with EcoRI-digested genomic DNA from tumour samples (Lanes 1–29) and normal lung tissues (Lane
N). Also shown is the internal control cardiac actin (C-Actin) band to which the cyclin D1 signal intensity was normalized for densitometer analysis. The relative
cyclin D1 gene amount was defined as the normalized cyclin D1 signal intensity in the tumour samples relative to that in the normal lung control (= 1.0). Relative
cyclin D1 gene amounts of 29 tumour samples ranged from 0.6 to 2.2. IHC: positive (+) or negative (–) nuclear staining for cyclin D1 determined by
immunohistochemistry. ND: not determinedcyclin D1 expression. Expression of cyclin D1 has been shown to
be up-regulated by a complex mechanism involving RB and p53,
and down-regulation can be caused by oncogenic proteins of trans-
forming DNA viruses, including SV40 large T antigen and E6 and
E7 proteins of the human papillomavirus, which are known to
inactivate tumour suppressor genes such as RB and p53 (Lukas et
al, 1994b; Müller et al, 1994; Chen et al, 1995; Spitkovsky et al,
1995; Del Sal et al, 1996; Marhin et al, 1996). In the present study,
cyclin D1 expression was observed not only in tumours with unal-
tered p53 and/or RB protein status but also in tumours with altered
expression of these proteins, suggesting that p53 and RB proteins
might not necessarily be involved in the regulation of cyclin D1
expression in NSCLCs. On the other hand, alterations of the path-
ways regulated by polypeptide growth factors such as epidermal
growth factor (EGF) (Ravitz et al, 1996; Zhu et al, 1996), and by
the ras oncogene product may contribute to cyclin D1 expression
(Filmus et al, 1994; Peeper et al, 1997). We determined expression
of the ras oncogene product by immunohistochemistry in this
cohort of NSCLCs, using our previously reported methods
(Harada et al, 1992). No significant association was observed
between cyclin D1 and ras oncogene expression (data not shown).
However, the association of cyclin D1 expression with K-ras
mutation and with EGF and EGF receptor expression in NSCLCs
remains to be determined.
In the present study, we found altered p53 protein expression
more frequently in cyclin D1+ tumours than in cyclin D1–
tumours. Co-expression of cyclin D1 and altered p53 protein has
been reported in uterine endometrial carcinomas (Nikaido et al,
1996). Similarly, Mineta et al (1997) reported a correlation
between p53 mutations and cyclin D1 amplification in head and
neck squamous cell carcinomas. These results, including ours,
suggest that abnormalities of cyclin D1 and p53 may present
simultaneously during the development and progression of cancer
(Uchimura et al, 1996), which is thought to represent a multistep
process involving the progressive accumulation of genetic alter-
ations (Fearon and Vogelstein, 1990).
The association of cyclin D1 expression with a higher Ki-67
index indicated increased growth potential of cyclin D1+ tumours.
Expression of cyclin D1 in early G1 is reported to promote cell
cycle progression through the G1 phase (Jiang et al, 1993). Ki-67
protein appears during the transition from G0 to G1, and remains
detectable for the remainder of the cell cycle and subsequent
cycles (Gerdes et al, 1984). This increased growth potential of
cyclin D1+ tumours may be reflected in more frequent expression
of cyclin D1 in tumours with advanced pT status (pT2–4) than in
pT1 tumours. Alternatively, frequent expression of cyclin D1 in
tumours with advanced pT status may indicate that cyclin D1
expression is a relatively late event in the development and
progression of NSCLCs.
Patients with cyclin D1+ NSCLCs showed longer survival
periods than those with cyclin D1– NSCLCs, and cyclin D1
expression tended to be a favourable prognostic factor in this
cohort of NSCLCs. These findings are similar to those reported by
others (Betticher et al, 1996, 1997; Nishio et al, 1997). Cyclin D1
seems to play a role not only in cell cycle promotion at the G1
checkpoint but also in the control of apoptosis (Sofer-Levi et al,
Cyclin D1 expression in NSCLCs 1293
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Figure 3 Kaplan–Meier survival curves of NSCLC patients who underwent
potentially curative resection. Survival curves of 77 such NSCLC patients are
stratified by cyclin D1 expression
Table 2 Ki-67 indices, and p53, p16 and RB protein expression in NSCLC
groups divided by cyclin D1 expression
Cyclin D1 expression
Characteristic (–) (+) P
Ki-67 indexa
Mean ± s.d. 20.3 ± 22.2 26.2 ± 17.5 0.08
Median 12.0 25.0
Range 1.0–92.0 1.8–64.6
p53b
p53– 60 4 0.04
p53+ 38 9
p16c
p16+ 69 11 0.5
p16– 27 2
RBd
RB+ 89 12 1.0
RB– 9 1
p16/RBe
p16/RB+ 60 10 0.4
p16/RB– 36 3
aDetermined for 91 cyclin D1– and 11 cyclin D1+ tumours. bp53– and p53+,
tumours without and with altered p53 protein expression respectively. cp16+
and p16–, tumours retaining and lacking normal p16 protein expression
respectively. dRB+ and RB–, tumours retaining and lacking normal RB protein
expression respectively. ep16/RB+, tumours retaining both p16 and RB
protein expression; p16/RB–, tumours lacking either p16 or RB protein
expression.
Table 3 Univariate analysis of potential prognostic factors in potentially
curatively resected NSCLCs
Hazard 95% Confidence
Characteristic ratio interval P
Age 0.99 0.95–1.03 0.5
Gender 1.89 0.78–4.62 0.2
Chemotherapy 1.74 0.85–3.5 0.1
Histological typea 1.41 0.38–5.18 0.6
pT classificationb 3.38 1.06–10.75 0.04
pN classificationc 3.47 1.45–8.33 0.005
pStaged 3.88 1.73–8.70 0.001
Cyclin D1 0.16 0.02–1.22 0.08
aSquamous cell carcinoma vs non-squamous cell carcinoma. bpT1 vs pT2–3.
cpN0 vs pN1–2. dpStage I vs pStage II–IIIa.1996) and growth suppresssion (Del Sal et al, 1996; Marhin et al,
1996). Such multifunctional properties of cyclin D1 may have
influence on a better clinical outcome of patients with cyclin D1+
NSCLCs. The present cohort included a limited number of poten-
tially curatively resected NSCLCs in pStages I to IIIa with rela-
tively short periods of observation after surgery. A larger study
that includes patients with homogeneous stages of disease in
longer periods of observation is currently ongoing, and will
determine whether cyclin D1 expression can predict the clinical
outcome of resected NSCLC patients.
In conclusion, the present study suggests that cyclin D1 expres-
sion may be involved in the development and progression of
NSCLCs, their high proliferative activity, and a favourable clinical
outcome.
ACKNOWLEDGEMENTS
The authors thank Dr T Hirata of National Sapporo Minami
Hospital, Sapporo, Japan, for providing resected NSCLC speci-
mens, and Dr M Fujita of the Department of Pathology, National
Sapporo Hospital, Sapporo, Japan, for providing an oesophageal
cancer specimen with cyclin D1 expression, which was used as a
positive control for immunostaining of cyclin D1. We also thank
Dr A Arnold of Massachusetts General Hospital, Boston, MA,
USA, and Dr F Gunning of Stanford University and Veterans
Affairs Medical Center, Palo Alto, CA, USA, for providing human
cyclin D1 and cardiac actin cDNAs respectively.
REFERENCES
Åkervall JA, Michalides RJAM, Mineta H, Balm A, Borg A, Dictor M, Jin Y, Loftus
B, Mertens F and Wennerberg JP (1997) Amplification of cyclin D1 in
squamous cell carcinoma of the head and neck and the prognostic value of
chromosomal abnormalities and cyclin D1 overexpression. Cancer 79:
380–389
Bartkova J, Lukas J, Strauss M and Bartek J (1994) Cell cycle-related variation and
tissue-restricted expression of human cyclin D1 protein. J Pathol 172: 237–245
Beahrs OH, Henson DE, Hutter RVP and Kennedy BJ (1992) Lung. In: Manual for
Staging of Cancer, 4th edn. American Joint Committee on Cancer: Chicago:
115–122
Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WDJ, Cerny T and
Thatcher N (1996) Prognostic significance of CCND1 (cyclin D1)
overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73:
294–300
Betticher DC, White GRM, Vonlanthen S, Liu X, Kappeler A, Altermatt H, Thatcher
N and Heighway J (1997) G1 control gene status is frequently altered in
resectable non-small-cell lung cancer. Int J Cancer 74: 556–562
Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI,
deFazio A, Watts CKW, Musgrove EA and Sutherland RL (1993) Expression
and amplification of cyclin genes in human breast cancer. Oncogene 8:
2127–2133
Chen X, Bargonetti J and Prives C (1995) p53, through p21 (WAF1/CIP1), induces
cyclin D1 synthesis. Cancer Res 55: 4257–4263
Del Sal G, Murphy M, Ruaro E, Lazarevic D, Levine A and Schneider C (1996)
Cyclin D1 and p21/waf1 are involved in p53 growth suppression. Oncogene
12: 177–185
Fearon ER and Vogelstein B (1990) A genetic model for colorectal tumorigenesis.
Cell 61: 759–767
Filmus J, Robles AI, Shi W, Wong MJ, Colombo LL and Conti C (1994) Induction
of cyclin D1 overexpression by activated ras. Oncogene 9: 3627–3633
Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U and Stein H (1984) Cell cycle
analysis of a cell proliferation-associated human nuclear antigen defined by the
monoclonal antibody Ki-67. J Immunol 133: 1710–1715
Hannon GJ and Beach D (1994) p15INK4B is a potential effector of TGF-b-induced
cell cycle arrest. Nature 371: 257–261
Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N and Kawakami Y (1992)
Prognostic significance of the expression of ras oncogene product in non-
small-cell lung cancer. Cancer 69: 72–77
Hinds PW, Dowdy SF, Eaton EN, Arnold A and Weinberg RA (1994) Function of a
human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91: 709–713
Jiang W, Tomita N, Zhang Y, Lu S and Weinstein B (1992) Amplification and
expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:
2980–2983
Jiang W, Kahn SM, Zhou P, Zhang Y, Cacace AM, Infante AS, Doi S, Santella RM
and Weinstein IB (1993) Overexpression of cyclin D1 in rat fibroblasts causes
abnormalities in growth control, cell cycle progression and gene expression.
Oncogene 8: 3447–3457
Kinoshita I, Dosaka-Akita H, Mishina T, Akie K, Nishi M, Hiroumi H, Hommura F
and Kawakami Y (1996) Altered p16INK4 and retinoblastoma protein status in
non-small-cell lung cancer: potential synergistic effect with altered p53 protein
on proliferative activity. Cancer Res 56: 5557–5562
Lovec H, Sewing A, Lucibello FC, Müller R and Möröy T (1994) Oncogenic
activity of cyclin D1 revealed through cooperation with Ha-ras: link
between cell cycle control and malignant transformation. Oncogene 9:
323–326
Lukas J, Pagano M, Staskova Z, Draetta G and Bartek J (1994a) Cyclin D1 protein
oscillates and is essential for cell cycle progression in human tumour cell lines.
Oncogene 9: 707–718
Lukas J, Müller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen-Durr P, Strauss M
and Bartek J (1994b) DNA tumor virus oncoproteins and retinoblastoma gene
mutations share the ability to relieve the cell’s requirement for cyclin D1
function in G1. J Cell Biol 125: 625–638
Lukas J, Parrr D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J
(1995) Retinoblastoma-protein dependent cell-cycle inhibition by the tumour
suppressor p16. Nature 375: 503–506
McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA,
Angus B, Lennard TWJ and Horne CHW (1995) Determination of the
prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11:
885–891
Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Gaeta P, La Rocca
R, Merlo G, Chella A, Angeletti CA, Palma PD and Bevilacqua G (1998)
Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small-cell
lung cancer. Int J Cancer 75: 187–192
Marhin WW, Hei Y, Chen S, Jiang Z, Gallie BL, Phillips RA and Penn LZ (1996)
Loss of Rb and myc activation co-operate to suppress cyclin D1 and contribute
to transformation. Oncogene 12: 43–52
Mate JL, Ariza A, Aracil C, Lopez D, Isamat M, Perez-Piteira J and Navas-Palacios
JJ (1996) Cyclin D1 overexpression in non-small-cell lung carcinoma:
correlation with Ki-67 labelling index and poor cytoplasmic differentiation.
J Pathol 180: 395–399
Matsushime H, Roussel MF, Ashmun RA and Sherr CJ (1991) Colony-stimulating
factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65:
701–713
Mineta H, Borg Å, Dictor M, Wahlberg P and Wennerberg J (1997) Correlation
between p53 mutation and cyclin D1 amplification in head and neck squamous
cell carcinoma. Oral Oncol 33: 42–46
Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM and
Arnold A (1991) A novel cyclin encoded by a bcl-1-linked candidate
oncogene. Nature 350: 512–515
Müller H, Lukas J, Schneider A, Warthoe P, Bartek J, Eilers M and Strauss M (1994)
Cyclin D1 expression is regulated by the retinoblastoma protein. Proc Natl
Acad Sci USA 91: 2945–2949
Naitoh H, Shibata J, Kawaguchi A, Kodama M and Hattori T (1995) Overexpression
and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J
Pathol 146: 1161–1169
Nakagawa H, Wang TC, Zukerberg L, Odze R, Togawa K, May GHW, Wilson J and
Rustgi AK (1997) The targeting of the cyclin D1 oncogene by an Epstein–Barr
virus promoter in transgenic mice causes dysplasia in the tongue, esophagus
and forestomach. Oncogene 14: 1185–1190
Nikaido T, Li S, Shiozawa T and Fujii S (1996) Coabnormal expression of cyclin D1
and p53 protein in human uterine endometrial carcinomas. Cancer 78:
1248–1253
Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M,
Shibagaki I, Nakao K, Ikenaga M and Ishizaki K (1994) Amplification and
overexpression of the cyclin D1 gene in aggressive human hepatocellular
carcinoma. Cancer Res 54: 3107–3110
Nishio M, Koshikawa T, Yatabe Y, Kuroishi T, Suyama M, Nagatake M, Sugiura T,
Ariyoshi Y, Mitsudomi T, Takahashi T and Takahashi TA (1997) Prognostic
significance of cyclin D1 and retinoblastoma expression in combination with
p53 abnormalities in primary, resected non-small-cell lung cancers. Clin
Cancer Res 3: 1051–1058
1294 T Mishina et al
British Journal of Cancer (1999) 80(8), 1289–1295 © 1999 Cancer Research Campaign Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA
and Ewen M (1997) Ras signalling linked to the cell-cycle machinery by the
retinoblastoma protein. Nature 386: 177–181
Ravitz MJ, Yan S, Dolce C, Kinniburgh AJ and Wenner CE (1996) Differential
regulation of p27 and cyclin D1 by TGF-b and EGF in C3H 10T1/2 mouse
fibroblasts. J Cell Physiol 168: 510–520
Serrano M, Hannon GJ and Beach D (1993) A new regulatory motif in
cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:
704–707
Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ and
Rollins BJ (1995) Reciprocal Rb inactivation and p16INK4 expression in primary
lung cancers and cell lines. Cancer Res 55: 505–509
Sherr CJ (1996) Cancer cell cycles. Science 274: 1672–1677
Sofer-Levi Y and Resnitzky D (1996) Apoptosis induced by ectopic expression of
cyclin D1 but not cyclin E. Oncogene 13: 2431–2437
Spitkovsky D, Steiner, Gopalkrishnan RV, Eilers M and Jansen-Dürr P (1995) The
role of p53 in coordinated regulation of cyclin D1 and p21 gene expression by
the adenovirus E1A and E1B oncogenes. Oncogene 10: 2421–2425
Tanaka H, Fujii Y, Hirabayashi H, Miyoshi S, Sakaguchi M, Yoon H and Matsuda H
(1998) Disruption of the RB pathway and cell-proliferative activity in non-
small-cell lung cancers. Int J Cancer 79: 111–115
Uchimura K, Endo K, Fujinuma H, Zukerberg L, Arnold A and Motokura T (1996)
Oncogenic collaboration of the cyclin D1 (PRAD1, bcl-1) gene with a mutated
p53 and an activated ras oncogene in neoplastic transformation. Jpn J Cancer
Res 87: 459–465
Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A and Schmidt EV (1994)
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.
Nature 369: 669–671
Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:
323–330
WHO (1982) Histological Typing of Lung Tumors, 2nd edn. pp. 25–26. World
Health Organization: Geneva
Zhu X, Ohtsubo M, Böhmer RM, Roberts JM and Assoian RK (1996) Adhesion-
dependent cell cycle progression linked to the expression of cyclin D1,
activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein.
J Cell Biol 133: 391–403
Cyclin D1 expression in NSCLCs 1295
British Journal of Cancer (1999) 80(8), 1289–1295 © 1999 Cancer Research Campaign 